Loading
Staar Surgical Co Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Mar 2026.
Staar Surgical Co: what insiders have been doing
Every trade that managers of Staar Surgical Co disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 7 insiders published 31 filings.
Every open-market trade in the period is a purchase: 5 purchases worth €11.8M, from 1 insider, and not a single sale. The totals exclude 1 filing filed without an amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Biggest ticket of the year: €7.1M, bought by Broadwood Partners, L.P. and made public on 21 November 2025. Among those who bought: 1 major shareholder and 1 senior executive.
The most recent open-market purchase was published on 13 March 2026, 219 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction.
With 31 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Our records for Staar Surgical Co go back to 2016, with 88 purchases and 15 sales on the open market in total. The 10-K for the year ended 2 January 2026 shows 239.4 m USD of revenue and -80.4 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
222
Thresholds
n/a
Buy Volume
€39M
88 ops. · all time
Sell Volume
€26M
15 ops. · all time
Who traded when
BuySaleBroadwood Partners, L.P.19 buys
Since the insiders bought
- +56.9%Entry US$18.08 · Close at T+90 US$28.37
- -22.7%Entry US$36.19 · Close at T+365 US$27.97
- -19.2%Entry US$31.32 · Close at T+365 US$25.31
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Staar Surgical Co Buy (bullish), based on 9 analysts. Average price target: US$28.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,002 of 24,148 companies
31.9
score / 100
Value22
Quality42
FCF yld-3.6%
Earn yld-7.2%
EV/EBITDA·
ROE1.1%
Gross mgn76%
Net mgn-34%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.26
Analyst consensus
9 analystsBuy
US$19.00Target US$28.00(+26%)US$37.00
Income statement
RevenueUS$239.4M
Gross profitUS$182.4M76% margin
EBITDA-US$37.2M-16% margin
Net income-US$80.4M1.1% margin
Valuation
PER (trailing)278.3x
PER (forward)20.0x
P/Book3.1x
Beta1.18
Balance sheet & cash
Market capUS$1.1B
Total debtUS$38.4M
Free Cash Flow-US$40.1M
Debt / Equity10%
Profitability & ownership
ROE1.1%
ROA5.6%
% insiders0.9%
% institutions111.6%
Last declaration on 18 August 2026
Declarations222 total
7,331 shares0Common StockSEC:0001970778-26-000014:0
3,666 shares0Common StockSEC:0001970778-26-000014:2
1,865 shares@ US$26.180.0047% mcap9.6% of flowCommon StockSEC:0001970778-26-000014:3
5,499 shares0Common StockSEC:0001731487-26-000011:0
2,797 shares@ US$26.180.0070% mcap32.7% of flowCommon StockSEC:0001731487-26-000011:1
559 shares@ US$26.180.0014% mcap6.5% of flowCommon StockSEC:0001731487-26-000011:2
1,100 shares@ US$26.180.0028% mcap12.9% of flowCommon StockSEC:0001731487-26-000011:3
5,233 shares0Common StockSEC:0001325697-26-000011:0
2,662 shares@ US$26.180.0067% mcap9.8% of flowCommon StockSEC:0001325697-26-000011:1
3,730 shares@ US$26.180.0094% mcap19.1% of flowCommon StockSEC:0001970778-26-000014:1
13,955 sharesCommon StockSEC:0001325697-26-000009:0
20,787 sharesCommon StockSEC:0001325697-26-000009:2
20,787 sharesCommon StockSEC:0001970778-26-000012:0
6,480 shares@ US$31.210.017% mcap28.8% of flowCommon StockSEC:0001325697-26-000009:1
10,576 shares@ US$24.360.025% mcap36.2% of flowCommon StockSEC:0001325697-26-000009:3
10,576 shares@ US$24.360.025% mcap50.5% of flowCommon StockSEC:0001970778-26-000012:1
5,341 sharesCommon StockSEC:0001678249-26-000003:0
1,877 shares@ US$32.070.0045% mcap8.4% of flowCommon StockSEC:0001325697-26-000006:3
3,755 shares@ US$32.070.0091% mcap16.8% of flowCommon StockSEC:0001325697-26-000006:1
10,466 shares0Common StockSEC:0001325697-26-000006:0
5,233 shares0Common StockSEC:0001325697-26-000006:2
8,175 shares0Common StockSEC:0001970778-26-000003:0
6,178 shares0Common StockSEC:0001731487-26-000002:0
54,764 shares@ US$17.52171.4% of flowCommon StockSEC:0000919574-26-001617:0
Canonical exit: 9 Jun 2026 (T+90)
25 of 222 declarations
About Staar Surgical Co
STAAR Surgical Co (NASDAQ: STAA) is a U.S.-based medical device company focused on ophthalmic surgery. Founded in 1982, the company has built its franchise around implantable lenses for vision correction and is headquartered in Lake Forest, California, United States. For international investors, STAAR is best viewed as a specialized healthcare technology name with exposure to structural demand trends in refractive surgery and to patient preferences for premium vision-correction options.
The company’s core business is the design, development, manufacturing, and sale of implantable collamer lenses (ICLs) and the related delivery systems used to implant them. Its flagship offering is the EVO family of lenses, built on its proprietary Collamer material and primarily used to treat myopia, with certain versions addressing additional refractive needs. STAAR’s products are positioned as premium alternatives to corneal laser procedures, targeting surgeons, hospitals, ambulatory surgery centers, and, in some markets, distributors. The business is concentrated in one reportable segment: ophthalmic surgical products.
Read moreShow less
In competitive terms, STAAR occupies a differentiated niche in refractive eye surgery. Rather than competing as a broad-based medtech platform, it focuses on a category where clinical expertise, surgeon adoption, product performance, and long-term brand credibility matter significantly. That specialization supports pricing power and product identity, but it also creates concentration risk. Demand can be affected by macroeconomic conditions, channel inventory swings, regulatory dynamics, and the pace of adoption in key markets.
STAAR sells globally, and its footprint is international. Historically, China has been an especially important market, which has made the company sensitive to changes in local demand, distributor inventories, and broader market conditions there. At the same time, the company maintains operations beyond the United States, including manufacturing-related capabilities in Switzerland. This global structure gives STAAR access to multiple growth markets, but it also means execution must be carefully managed across regions.
Recent developments suggest a transitional phase for the business. Company disclosures in 2025 and 2026 point to leadership changes, tighter cost control, supply-chain optimization, and a renewed emphasis on commercial discipline and sustainable profitability. The most recent reported results in 2026 highlighted a recovery in gross margin and more resilient performance outside China, while management also emphasized strategic resets intended to restore growth. In that context, STAAR Surgical on NASDAQ remains a focused ophthalmic franchise with meaningful upside tied to execution, product adoption, and a successful turnaround in its key geographic markets.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
